Work

Phase 1/2 study of investigational hypoxia-targeted drug, TH-302, and bevacizumab (bev) in recurrent glioblastoma (GBM) following bev failure.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.2029

Authors: Andrew Jacob Brenner, Jessica D Sun, John Floyd, Charles P Hart, Clarence Eng, Stew Kroll, Lisa Fichtel, Aleksandra Gruslova, Alessia Lodi, Stefano Tiziani

Institutions: The University of Texas at San Antonio Health Science Center, Threshold Pharmaceuticals (United States), South Texas Accelerated Research Therapeutics

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2908434170

Cites:

Cited by: 1

Related to: 10